Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE: To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal. RESEARCH DESIGN AND METHODS: Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) in...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ahrén, Bo, Foley, James E., Ferrannini, Ele, Matthews, David R., Zinman, Bernard, Dejager, Sylvie, Fonseca, Vivian A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Diabetes Association 2010
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2845014/
https://ncbi.nlm.nih.gov/pubmed/20067974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-1867
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky